Bansal, M and Chan, J and Leano, R and Pillans, P and Horowitz, J and Marwick, TH, Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction, International Journal of Cardiology, 139, (2) pp. 107-112. ISSN 0167-5273 (2010) [Refereed Article]
Copyright 2010 Elsevier Ireland
Methods Thirty-six medically-treated patients, stable at least 6 months post-infarction with LV dysfunction and myocardial viability shown by dobutamine echo (DbE) were randomised to receive perhexiline or matching placebo for 1 year. Cardiopulmonary exercise testing and DbE were performed at baseline and follow-up. Peak-systolic strain (S) and strain rate (SR) were measured offline in 111 dysfunctional segments in the placebo and 88 in the treatment group at rest, low-dose (LDD) and peak-dose dobutamine (PDD).
Results The serum perhexiline level was 0.27 ± 0.7 µg/l. There was no difference in the wall motion response to dobutamine at baseline and follow-up. Resting strain and SR were similar in the two groups at baseline and follow-up. However, SR at LDD and PDD increased in the placebo group and worsened during the same period in the perhexiline group. Patients on perhexiline and placebo had a similar rate-pressure product and exercise duration at baseline (7.9 ± 2.7 vs 8.7 ± 3.3 min, p = NS) and follow-up (9.6 ± 4.6 vs 10.1 ± 3.03 min, p = NS).
Conclusion Perhexiline does not improve the deformation of abnormal myocardial segments in patients with ischaemic LV dysfunction.
|Item Type:||Refereed Article|
|Research Division:||Medical and Health Sciences|
|Research Group:||Cardiorespiratory Medicine and Haematology|
|Research Field:||Cardiology (incl. Cardiovascular Diseases)|
|Objective Group:||Clinical Health (Organs, Diseases and Abnormal Conditions)|
|Objective Field:||Cardiovascular System and Diseases|
|Author:||Marwick, TH (Professor Tom Marwick)|
|Web of Science® Times Cited:||5|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page